Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Mtech Access are exhibiting at ISPOR in the US

    March 21, 2024 | HEOR, Market Access, Patient-centricity, Pricing, ispor, real-world evidence 

    After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125 to discover how they partner with Pharma and Medtech leaders to drive optimal global commercialisation by challenging them to think differently.

    Meet us at ISPOR

    Mtech Access are delighted to announce that they will be exhibiting at the ISPOR conference in Atlanta, Georgia, USA this May 5-8. As regular attendees of ISPOR Europe, the team are excited to be attending this global conference for the first time, where they plan to meet some of their US-based clients on their home turf.

    The team are inviting Pharmaceutical and Medical Device companies to meet with them at booth 125. Visitors to the stand are invited to put their questions to Mtech Access experts. Those who book a meeting in advance will benefit from:

    • Dedicated time with the most relevant experts, who will discuss your challenges and opportunities
    • A structured agenda for the conversation targeting your areas of focus
    • Market and disease area-specific resources and insights
    • 1 hour of free consultancy with their expert team, redeemable after the conference

    To arrange a time to meet, complete this form or email info@mtechaccess.co.uk.

    “We are delighted to be attending the ISPOR conference in the USA this year. We are eager to make new connections, reconnect with old friends, and forge lasting partnerships during this exciting event. We are particularly looking forward to exploring key themes in the HEOR space, such as real-world evidence, patient centricity, and drug pricing.” – Lydia Crowe, Commercial Director.

    About Mtech Access

    Mtech Access partner with Pharma and Medtech leaders to drive optimal global commercialisation. Their programmes of support include:

    • Evidence, pricing and access strategy
    • Development of a robust evidence base
    • National, regional, and local reimbursement, and formulary inclusion
    • Communication of value to clinical and financial decision-makers

    Their clients benefit from collaborative, expert-driven, solutions-focused partnerships. The team have extensive experience in all therapy areas and deep expertise in rare disease, oncology, respiratory, diabetes and obesity, neurology, and immunology.

    https://mtechaccess.co.uk/

    This content was provided by Petauri Evidence